Angle PLC Parsortix in multiple presentations at AACR
April 19 2018 - 2:01AM
RNS Non-Regulatory
TIDMAGL
Angle PLC
19 April 2018
For immediate release 19 April 2018
ANGLE plc ("the Company")
ANGLE'S PARSORTIX SYSTEM SHOWCASED IN MULTIPLE PRESENTATIONS AT
LEADING CANCER CONFERENCE AACR 2018
Customers and collaborators publish more successful research
with ANGLE's Parsortix circulating tumor cell (CTC) harvesting
system in four poster presentations
Well positioned to become the CTC liquid biopsy system of
choice
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company, today announces that its Parsortix(TM) system was widely
showcased by the Company's customers and Key Opinion Leaders in the
field of circulating tumour cells (CTCs) in presentations at the
American Association for Cancer Research conference (AACR) 2018, in
Chicago, 14 to 18 April 2018.
ANGLE Founder and Chief Executive, Andrew Newland,
commented:
"The multiple presentations featuring the Parsortix system at
this leading conference for cancer research continues to
demonstrate that ANGLE's strategy of promoting the adoption of its
CTC harvesting system as the de facto standard for harvesting
cancer cells for analysis is working well and generating further
utility and evidence of effectiveness. The Parsortix system is
compatible with numerous downstream analysis systems and our aim is
for it to become the CTC system of choice for cancer liquid biopsy,
a growing market that is expected to reach $14 billion in the
United States alone by 2025. In pursuit of this objective,
following highly successful trials in ovarian cancer, ANGLE has a
pivotal clinical study for metastatic breast cancer in progress
with the aim of becoming the first company ever to receive FDA
clearance for a product to harvest CTCs from blood for subsequent
analysis."
ANGLE's Parsortix system was showcased in the following four
different poster presentations by leading cancer centres:
Poster Presentations
1) Robert H Lurie Comprehensive Cancer Center and the Feinberg
School of Medicine, Northwestern University, Chicago
(Northwestern): optimised workflow for the recovery and culturing
of CTCs from a simple blood test to produce an effective ex-vivo
culture of the patient's cancer cells (see separate announcement
released today describing this breakthrough work)
2) Boehringer Ingelheim and University Hamburg-Eppendorf:
Detection of CTCs in NSCLC (non-small cell lung cancer) as part of
the pan-European Cancer-ID programme which is seeking to
standardise protocols for clinical adoption across Europe
3) University of Athens: FISH (fluorescence in situ
hybridisation) analysis of CTCs for NSCLC cancer patients to
identify HER-2 and c-MET CTCs that may indicate tumor resistance to
kinase inhibitor drugs
4) Bayer AG: analysis of DNA mutations in NSCLC using highly
sensitive droplet digital PCR as part of the pan-European Cancer-ID
programme which is seeking to standardise protocols for clinical
adoption across Europe.
When the posters have been publicly released, they will be
available on ANGLE's website at
https://angleplc.com/library/publications/
For further information ANGLE:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
finnCap Ltd (NOMAD and Joint Broker)
Corporate Finance - Adrian Hargrave,
Simon Hicks, Kate Bannatyne
Corporate Broking - Alice Lane, Nikita
Jain +44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes, Nigel Birks, Andrew Craig,
Chris Lee +44 (0) 203 705 9330
FTI Consulting
Simon Conway, Mo Noonan, Stephanie Cuthbert +44 (0) 203 727 1000
Evan Smith, Anne Troy (US) +1 212 850 5612
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world leading liquid biopsy company with sample to
answer solutions. ANGLE's proven patent protected platforms include
an epitope-independent circulating tumor cell (CTC) harvesting
technology and a downstream analysis system for cost effective,
highly multiplexed analysis of nucleic acids and proteins.
ANGLE's cell separation technology is called the Parsortix(TM)
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in Europe, the United States, Canada, India, China,
Japan and Australia and three extensive families of patents are
being progressed worldwide. The system is based on a microfluidic
device that captures live cells based on a combination of their
size and compressibility. The Parsortix system has a CE Mark for
Europe and FDA clearance is in process for the United States.
ANGLE's analysis technology for proteins and nucleic acids of
all types is called Ziplex(R) and is based on a patented flow
through array technology. It provides for highly multiplexed, rapid
and sensitive capture of targets from a wide variety of sample
types. A proprietary chemistry allows for the capture and
amplification of over 100 biomarkers simultaneously in a single
reaction. These technologies can be combined to provide fully
automated, sample to answer results in both centralised laboratory
and point of use cartridge formats. It is ideal for measuring gene
expression and other markers directly from Parsortix harvests.
ANGLE has established formal collaborations with world-class
cancer centres. These Key Opinion Leaders are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. Details are available here
http://www.angleplc.com/the-company/collaborators/
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAFKFDNKBKBDQD
(END) Dow Jones Newswires
April 19, 2018 02:01 ET (06:01 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024